Importantly, just as there are multiple paths to developing NAFLD/NASH, multiple treatment strategies will likely be needed, and augmenting GH/IGF-1 may not be an effective strategy for all individuals. Here, GH1 is linked to metabolic dysfunction-associated steatotic liver disease.